US Patent No. US20260007382 related to the uTomo Platform Technology and its first-generation product technology – META CT | AI technology has been granted, solidifying IP protections for XENSE in method, apparatus and chemistry.

Since the 1970’s, it has been believed by imaging scientists and the CT physics community that unless the angles between images acquired for 3D reconstruction are larger than 10 or 15 degrees (” the limited angle problem”), a high-quality 3D image cannot be achieved. The toroid CT is considered the gold standard of 3D imaging because image acquisitions can be made at the widest angle possible, => 180 degrees, is therefore more accurate.  XENSE has proved the contrary – META CT technology based on uTomo Platform Technology has been validated in our lab and one of the first related patents has now been granted by USPTO.

Standardization, Accuracy & Ground Truth Data are to be offered by a compact, ultralow radiation device, replacing traditional CT, general x-ray, fluoroscope and densitometer with much better imaging performance and efficiency.

Adding proprietary META AI solutions, designed to further automation and applications of META CT, XENSE aims to offer an end-to-end technology solution to revolutionize medical imaging and AI by minimizing radiology error and save time throughout the healthcare delivery workflow: Prediction, Diagnosis, Intervention Decision Making, Planning & Guidance, and Post Treatment Monitoring.

 

 

*uTomo based products and META CT | AI are underdevelopment, not yet FDA approved and not for sale currently.